Media headlines about ReWalk Robotics (NASDAQ:RWLK) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ReWalk Robotics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 46.6684437073715 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
A number of analysts have commented on RWLK shares. Jefferies Group decreased their price objective on ReWalk Robotics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Canaccord Genuity reissued a “buy” rating and set a $3.00 price objective on shares of ReWalk Robotics in a report on Monday, November 6th. Finally, Zacks Investment Research raised ReWalk Robotics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $3.00.
Shares of ReWalk Robotics (NASDAQ RWLK) traded down $0.05 on Tuesday, reaching $1.10. The company’s stock had a trading volume of 543,000 shares, compared to its average volume of 402,609. The company has a debt-to-equity ratio of 7.46, a current ratio of 2.02 and a quick ratio of 1.65. ReWalk Robotics has a 1 year low of $1.05 and a 1 year high of $3.60.
ReWalk Robotics (NASDAQ:RWLK) last announced its earnings results on Thursday, November 2nd. The medical device company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.10. ReWalk Robotics had a negative return on equity of 568.25% and a negative net margin of 346.14%. The firm had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.63 million. During the same quarter in the previous year, the business earned ($0.62) EPS. The company’s revenue was up 21.4% compared to the same quarter last year. analysts expect that ReWalk Robotics will post -1.14 EPS for the current year.
WARNING: “ReWalk Robotics (RWLK) Receiving Somewhat Favorable Media Coverage, Study Finds” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/rewalk-robotics-rwlk-receiving-somewhat-favorable-media-coverage-study-finds.html.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with MarketBeat.com's FREE daily email newsletter.